Odronextamab not checked
Regeneron · REGN1979 · R1979
FollowEvery change as it happens, and a Monday email
Trials
10 active
11 in total · 9 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Odronextamab will be administered by intravenous (IV) infusion”In the company’s words, NCT06091865 on ClinicalTrials.gov
- Tested for
- Follicular Lymphoma (FL) (2 trials), Diffuse Large B-cell Lymphoma (DLBCL) (2 trials), B-Cell Non-Hodgkin Lymphoma (B-NHL) (2 trials), Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL), B-cell Non-Hodgkins Lymphoma (B-NHL), Lupus Nephritis (LN)
- Main trialPhase 3
- “This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone. The aim of Part 2 of the study is to see how the study drug works compared to rituximab (called the "comparator drug") and chemotherapy (the current standard of care for…”In the company’s words, NCT06091254 on ClinicalTrials.gov
- Other names
- REGN1979 · Ordspono · R1979
Other drugs for Follicular Lymphoma (FL)
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- TazemetostatEpizyme, Inc. · Phase 3
- EpcoritamabGenmab · Phase 3
- SurovatamigAstraZeneca · Phase 3
- GolcadomideCelgene · Phase 3
- SCTB35Sinocelltech · Phase 3
Coming up8
- 29 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- 29 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 16 Feb 2029Phase 1 trial completes · ClinicalTrials.gov
- 29 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
- 10 Sep 2029Phase 1 trial completes · ClinicalTrials.gov
- 1 Nov 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Apr 2031Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovCompletion date moved: 2028-02-07 to 2028-02-29 · ClinicalTrials.gov NCT06091254
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 29 Feb 2028 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | |
| Phase 3Recruiting | 30 Mar 2028 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | |
| Phase 3Active, not recruiting | 29 May 2028 | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | |
| Phase 3Active, not recruiting | 29 Jul 2029 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma | |
| Phase 3Recruiting | 30 Apr 2031 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | |
| Phase 2Active, not recruiting | 17 Jun 2026 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies | |
| Phase 1/2Not yet recruiting | 1 Nov 2029 | REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) | |
| Phase 1Recruiting | 16 Feb 2029 | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas | |
| Phase 1Recruiting | 10 Sep 2029 | Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis | |
| Phase 1Completed | 29 Apr 2026 | A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies | |
| Phase 2/3Authorised | not given | Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026